Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05138796 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic Study of TP-05 in Healthy Subjects

A Phase 1 study, sponsored by Tarsus Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
67
Enrollment target

NCT05138796: Completed Phase 1 study, sponsored by Tarsus Pharmaceuticals.

NCT05138796 is a Phase 1 study that has completed, run by Tarsus Pharmaceuticals. The registered enrollment target is 67 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05138796, a Phase 1 study, has completed, sponsored by Tarsus Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
67 participants
Enrollment target

Study Summary

A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects

Primary Outcome

Evaluate the safety of TP-05 through the incidence rate of TEAEs

Interventions

  • DRUG Placebo
  • DRUG TP-05 (lotilaner oral capsules)

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2021-05-06
Est. Completion 2022-07-25
Phase Phase 1
Tarsus Pharmaceuticals

9 total trials

What the finished NCT05138796 record still lists

NCT05138796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05138796 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05138796 about?

NCT05138796 is a clinical study titled "A Pharmacokinetic Study of TP-05 in Healthy Subjects". A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects

What is the current status of trial NCT05138796?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2021-05-06. Estimated completion is 2022-07-25.

What interventions are being tested in trial NCT05138796?

The interventions under investigation include: Placebo (DRUG), TP-05 (lotilaner oral capsules) (DRUG).

Who is sponsoring clinical trial NCT05138796?

This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05138796's enrollment target sits among peer trials

67 782nd of 2000 higher than 1,215 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03213002 · 67 participants · Phase 1

    Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

  • NCT04115163 · 67 participants · Phase 2

    Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

  • NCT04315324 · 67 participants · Phase 1

    Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

  • NCT04532424 · 67 participants · NA

    Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05138796, the US trial registry maintained by the National Library of Medicine. NCT05138796 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.